Introduction {#sec1}
============

Bloodstream infections, especially in intensive care units, are among the most important causes of morbidity and mortality despite the antimicrobial treatment. The early diagnosis and treatment of these infections is clinically vital ([@bib9]; [@bib10]). For the proper identification and antibiotic susceptibility testing, the bacteria grown in blood culture bottles are sent to laboratories; the detection of bloodstream infections under the appropriate growth conditions, at the appropriate periods, and using the appropriate conventional methods constitute a significant portion of microbiological testing. The recently developed automated systems have been shown to be suitable for bacterial culture, and upon detection of a growth signal, clinicians can remove the bottles from the device and inoculate the sample into media. These media generally include resins or coal particles that absorb antimicrobial agents or other substances that inhibit bacterial growth and may be present in the patient's blood sample ([@bib19]; [@bib14]; [@bib20]; [@bib13]). Early and correct treatment of patients is essential for reducing morbidity and mortality.

For this reason, rapid identification of microorganisms and antibiotic susceptibility testing is crucial. Due to Gram staining of microorganisms in blood cultures, their identification and antibiotic sensitivity results are obtained early, clinicians are informed quickly, and the patient is given the opportunity to start early antibiotic treatment. Continuous monitoring of automated blood culture systems allows a positive blood culture to be detected within 6 to 24 hours of incubation ([@bib19]; [@bib4]; [@bib10]; [@bib14]; [@bib20]).

In recent years, advances in the methods involving polymerase chain reaction and DNA sequencing have changed the nature of clinical microbiology laboratories. However, the lack of diagnostic tests that are fast, reliable, easy to use, and inexpensive, as well as applicable for use as diagnostic checkpoints is a significant limitation ([@bib25]; [@bib26]; [@bib5]). Although several molecular or proteomic methods (e.g., Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry \[MALDI-TOF MS\]) exist that can be used to direct evaluation of specimens or colonies, the gold-standard methods with the highest sensitivity and safety still remain blood culture-based methods ([@bib17]; [@bib4]; [@bib25]; [@bib26]; [@bib20]; [@bib5]; [@bib13]).

This study aimed to use a different, faster-than-usual method, which involves centrifugation at 12 hours of bacterial culture to allow clinicians to rapidly (in less than 12 hours) complete the antibiotic susceptibility testing. It may be due to more accurate information about the Gram-staining characteristics of growing microorganisms via a positive signal of microbial growth in the incubator.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

**Clinical samples**. The study included 152 bottles of blood culture (aerobic, pediatric blood culture vials, BD, USA), which gave positive signals in the first 12 hours in the incubator (Bactec FX, BD, USA) out of 2,455 blood culture samples sent from different clinics of our hospital to the Medical Microbiology Laboratory between August 2018 and July 2019. Of these 152 blood culture bottles, 102 were sent from intensive care units, 31 from internal sciences clinics, and 19 from surgical sciences clinics. Of these, 130 belonged to adult patients (≥ 18 years old), and 22 belonged to pediatric patients (\< 18 years old).

**The rapid method. Centrifugation**. Five ml of the inoculating fluid was taken from the positive blood culture vials, and, unlike in the routine procedure, the centrifugation was conducted in a standard blood collection tube (BD Vacutainer 5.0 ml, BD, USA) at 2,000 rpm for 10 minutes. After centrifugation, the blood components (erythrocytes, etc.) were placed under a gel, and the bacteria in the serum adhered to the gel to provide a gelatinous coating that formed a film layer. Then, the supernatant liquid remaining on the gel in the collection tube was slowly discharged. A small number of the bacteria collected in the form of a layer on the gel in the collection tube was removed with a cotton swab and spread on a sterile microscope slide for Gram staining.

**Gram staining**. After the serum fraction was removed, a few bacteria were taken from the bacterial film layer just above the gel. Then, a small volume of this layer was spread and air-dried on a slide. The air-dried preparations were subjected to Gram staining ([@bib2]) using a Gram-staining set (Moslab, Ankara, Turkey). For this, crystal violet was poured onto the slide, left for 2 minutes, and washed with water. Then, the Lugol solution was poured, left for 2 minutes, washed with water, then decolorized with alcohol and washed with water. Finally, diluted fuchsin was poured onto the slide, and after 30 seconds, the preparation was washed with water and allowed to air-dry. The preparations were then examined with a microscope with a 100 × objective. Based on the results of the study, the strains were defined as Gram-positive or Gram-negative (Figs. [1](#fig1){ref-type="fig"}--[4](#fig4){ref-type="fig"}).

![Microscopic appearance of Gram-positive bacteria after Gram staining with the routine method at a magnification of 1000×.](pjm-69-2-165-g001){#fig1}

![Microscopic appearance of Gram-positive bacteria after Gram staining with the rapid method at a magnification of 1000×.](pjm-69-2-165-g002){#fig2}

![Microscopic appearance of Gram-negative bacteria after Gram staining with the routine method at a magnification of 1000×.](pjm-69-2-165-g003){#fig3}

![Microscopic appearance of Gram-negative bacteria after Gram staining with the rapid method at a magnification of 1000×.](pjm-69-2-165-g004){#fig4}

**Identification and antibiotic susceptibility testing using the rapid method**. After Gram staining, the strains of Gram-positive and Gram-negative bacteria or yeast were picked from the gel with a cotton-tipped extruder. Bacteria of a concentration equivalent to a McFarland standard of 0.5--0.63 (for yeasts, 1.8--2.2) were diluted with the manufacturer's identification solution (ID broth, BD, USA). Then, 0.5 μl of the dilution was transferred to the antibiotic susceptibility test solution (AST broth, BD, USA), and identification and antibiotic susceptibility tests were conducted using an automated identification and susceptibility testing system (Phoenix 100, BD, USA) and the appropriate kits (GP ID/AST, GN ID/AST or YEAST ID, BD, USA). The tests run for an average of 8--12 hours, depending on the type of microorganism. The results were reported quickly within 24 hours by the clinician involved.

**The routine procedures**. For comparison, the microorganisms from bottled blood samples were also cultured on sheep blood agar (SBA), eosin methylene blue (EMB) agar, and some other media without centrifugation and routinely incubated at 37°C for 18--24 hours. The next day, when sufficient growth was observed, routine Gram-staining and antibiotic susceptibility testing were performed. With the help of a sterile loop, a small volume of the colonies grown on the medium was taken and mixed in the identification broth (ID broth, BD, USA). Then, 0.5 μl of the dilution was transferred to the solution for antibiotic susceptibility testing (AST broth, BD, USA). Both solutions were transferred to the appropriate kits. Identification and antibiotic susceptibility tests were conducted using the automated identification and susceptibility testing system (Phoenix 100, BD, USA), and the appropriate kits (GP ID/AST or GN ID/AST, BD, USA). The tests were run for an average of 8--12 hours, depending on the type of microorganism. The results were reported quickly, within 24 hours, by the clinician involved.

**MALDI-TOF MS Analysis**. The samples were collected with the aid of a sterile loop from colonies of microorganisms grown on the appropriate medium using a routine method, and each bacterial or yeast isolate was transferred to a separate well on a distinct plate in the MALDI-TOF system. One microliter of 70% formic acid (FA) (FA extraction solution, Bruker Daltonik GmbH, Germany) was added to the plate, and after drying at room temperature, 1 μl of α-cyano-4-hydroxycinnamic acid matrix solution (HCCA) (IVD Matrix HCCA, Bruker Daltonik GmbH, Germany) was again dried at room temperature (20--25°C). The dried plates were placed in the instrument (MSP 96 target polished steel, Bruker Daltonik GmbH, Germany) and loaded onto the MALDI-TOF MS (Bruker, Germany) for analysis. At the end of the analysis, the reported microorganisms were recorded using a particular software system (IVD MALDI Biotyper, Bruker Daltonik GmbH, Germany) ([@bib21]). For the scoring used in the identification, values were in the range from 0 to 3. Microorganisms with a score ≥ 2 were evaluated as correctly identified at the genus and species level. A score of 1.7--2 given to organisms indicated a correct identification at the genus level. Organisms with a score of \< 1.7 were identified as those that required testing again.

**Data analysis**. In terms of identification, in the Phoenix 100 Expert System's interpretation, organisms with a reliability \> 90 were accepted as being correctly identified. Those with a value of \< 90 were considered incorrectly identified. In terms of susceptibility, the minimum inhibitory concentration (MIC) values of the bacteria against the antimicrobials evaluated by both the rapid and routine method were translated into clinical categories (susceptible \[S\], intermediate \[I\], or resistant \[R\]) according to the Phoenix 100 Expert System's interpretive criteria.

For comparison of the results of both methods, the Clinical and Laboratory Standards Institute (CLSI) M52 Verification of Commercial Microbial Identification and Antimicrobial Susceptibility Testing System ([@bib6]) was used. According to this methodology, the identification results were divided into three categories: not identified, misidentified (organism was incorrectly identified at the genus or species level \[discrepancy\]), and full consistency (accurate identification at the same genus and species level by both methods). For the antibiotic susceptibility results, the discrepancies were classified as minor errors (mEs: susceptible/resistant versus intermediate susceptibility), major errors (MEs: false resistant, considered as resistant susceptibility by one method but susceptible by the other method), and very major errors (VMEs: false susceptibility).

**Statistical analysis**. The statistical analyses were performed using software (SPSS 15.0, IBM, USA). The results of the continuous data analyses were given as minimum, maximum, median, and mean values, and the results of some categorical variables were given as frequencies and percentages.

Results {#sec4}
=======

A positive signal, which was a bacterial growth marker, was recorded for 152 bottles of blood culture included in the study. They were sent from 102 (67.1%) intensive care units (84 internal intensive care, nine coronary intensive care, and nine pediatric intensive care), 31 (20.4%) from internal clinics (15 internal medicine clinics, ten oncology/hematology clinics, and six pediatric clinics), and 19 (12.5%) from surgical clinics (10 general surgery clinics, seven pediatric surgery clinics, and two gynecology clinics). Of the 152 samples, 130 (85.5%) came from adult patients and 22 (14.5%) from pediatric patients. Of the patients, 82 (54%) were female, 70 (46%) were male, and the youngest patient was one year old, while the oldest was 89 years old (their mean age was 57.5). Because of the lack of blood-based elements in the bacterial layer and the presence of a more significant number of microorganisms than usual, the images of the microorganisms obtained by microscopic examination following Gram staining after centrifugation were more satisfactory in terms of their quality and quantity than those obtained following Gram staining without centrifugation.

According to the results obtained, of the 152 samples included in the study, 150 (98.7%) contained only one type of bacteria. While 116 (77.3%) of these 150 strains stained as Gram-positive (107 cocci and nine bacilli), and 30 (20%) stained as Gram-negative bacilli. The remaining four strains (2.7%) stained as Gram-positive, but they were placed in a separate category because they were yeast. In the other two (1.3%) samples, two bacterial species (*Escherichia coli* and *Staphylococcus aureus*), one Gram-positive and one Gram-negative were detected. In the microscopic examination of the stained cells, these two specimens, that contained more than one type of microorganism, were not evaluated because these bacteria could not be separately tested for antibiotic susceptibility and because the bacteria must be inoculated onto appropriate media. In other words, these two samples were passaged and terminated 18--24 hours after incubation according to routine procedures.

For the identification and antibiotic susceptibility testing, 116 (77.3%) of the 150 microbial strains were analyzed using GP ID/AST kits because these strains were detected as being Gram-positive by Gram staining, and 30 (20%) strains evaluated using GN ID/AST kits because these strains were detected as being Gram-negative by Gram staining. Furthermore, four samples were determined using a YEAST/ID kit because they were observed as yeast in the Gram staining (Table [I](#tbl1){ref-type="table"}).

###### 

Distribution of microorganisms detected by Gram staining after centrifugation according to the rapid method procedure.

![](pjm-69-2-165-t001)

  Gram-staining result                          n (%)
  --------------------------------------------- -------------
  Gram-positive cocci                           107 (70.4)
  Gram-negative bacilli                           30 (19.7)
  Gram-positive bacilli                             9 (5.3)
  Gram-positive cocci + Gram-negative bacilli       2 (1.3)
  Yeast (*Candida* spp.)                            4 (2.6)
  Total number of samples                       152 (100)

n -- number

According to the results obtained the following morning, of the 116 Gram-positive strains studied by MALDI-TOF MS analysis, 71 (61.2%) were identified as coagulase-negative *Staphylococcus* (CoNS), and seven (6.0%) were identified as *Staphylococcus aureus* (one isolate, identified as *S. epidermidis*, was, in fact, methicillin-resistant *S. aureus* \[MRSA\] as demonstrated with both the routine method and the MALDI-TOF system), while 20 (17.2%) were *Enterococcus* species. These values, when studied by the routine method, were as follows: 76 (65.5%), 8 (6.9%), and 20 (17.2%), respectively. No isolates of vancomycin-resistant enterococci (VRE) were found in this study. In addition, 15 (50%) of Gram-negative isolates were identified as *E. coli*, five as *P. aeruginosa*, five as *Klebsiella pneumoniae*, three as *Stenotrophomonas maltophilia*, and two as *Acinetobacter baumannii*. When the yeast isolates were analyzed using the appropriate kit (YEAST/ID, BD, USA) and the appropriate McFarland (1.8--2.2) standard (BD PhoenixSpec, BD, USA), the results obtained by both methods were found to be fully compatible (two of the four specimens were identified as *Candida parapsilosis* and the other two as *Candida tropicalis*) (Table [II](#tbl2){ref-type="table"}).

###### 

Distribution of bacteria identified by both methods at the genus and species level.

![](pjm-69-2-165-t002)

  Rapid method                                    n (%)           Routine method                                    n (%)
  ----------------------------------------------- --------------- ------------------------------------------------- ---------------
  **[Gram-positive bacteria (total)]{.ul}**       **116**         **[Gram-positive bacteria (total)]{.ul}**         **116**
  ***[Staphylococcus aureus]{.ul}***                7 (6.0)       ***[Staphylococcus aureus]{.ul}***                  8 (6.9)
  MRSA: 2, MSSA: 5                                                MRSA: 3, MSSA: 5                                  
  ***[Coagulase-negative Staphylococci]{.ul}***   **71 (61.2)**     ***[Coagulase-negative Staphylococci]{.ul}***   
  *Staphylococcus epidermidis: 45*                                *Staphylococcus epidermidis: 48*                  **76 (65.5)**
  *Staphylococcus hominis*: *16*                                  *Staphylococcus hominis*: *18*                    
  *Staphylococcusschleiferi: 4*                                   *Staphylococcusschleiferi: 4*                     
  *Staphylococcus haemolyticus: 2*                                *Staphylococcus haemolyticus: 2*                  
  *Staphylococcus capitis: 2*                                     *Staphylococcus capitis: 2*                       
  *Staphylococcus warneri: 2*                                     *Staphylococcus warneri: 2*                       
  ***[Enterococci]{.ul}***                        **20 (17.2)**     ***[Enterococci]{.ul}***                        **20 (17.2)**
  *Enterococcus faecalis: 18*                                     *Enterococcus faecalis: 18*                       
  *Enterococcus faecium:* 2                         3 (2.6)       *Enterococcus faecium:* 2                           2 (1.8)
  *Arcanobacterium haemolyticum*                    3 (2.6)       *Arcanobacterium haemolyticum*                      2 (1.8)
  *Bacillus cereus*/*subtilis*                      2 (1.8)       *Bacillus subtilis*                                 2 (1.8)
  *Dermacoccus nishinomiyaensis*                    4 (3.5)       *Dermacoccus nishinomiyaensis*                      2 (1.8)
  *Micrococcus luteus*/*lylae*                      3 (2.6)       *Micrococcus luteus*/*lylae*                        2 (1.8)
  *Corynebacterium amycolatum*                      3 (2.6)       *Corynebacterium amycolatum*                        2 (1.8)
  *Corynebacterium jeikeium*                                      *Corynebacterium jeikeium*                        
  **[Gram-negative bacteria (total)]{.ul}**       **30**            **[Gram-negative bacteria (total)]{.ul}**       **30**
  *Escherichia coli*                              15 (50)         *Escherichia coli*                                15 (50)
  *Pseudomonas aeruginosa*                          5 (16.7)      *Pseudomonas aeruginosa*                            5 (16.7)
  *Klebsiella pneumoniae*                           5 (16.7)      *Klebsiella pneumoniae*                             5 (16.7)
  *Stenotrophomonas maltophilia*                    3 (10.0)      *Stenotrophomonas maltophilia*                      3 (10.0)
  *Acinetobacter baumannii*                         2 (6.7)       *Acinetobacter baumannii*                           2 (6.7)
  **[Yeasts]{.ul}**                                 **4**           **[Yeasts]{.ul}**                                 **4**
  *Candida parapsilosis*                            2 (50)        *Candida parapsilosis*                              2 (50)
  *Candida tropicalis*                              2 (50)        *Candida tropicalis*                                2 (50)

MRSA -- methicillin-resistant *Staphylococcus aureus*; MSSA -- methicillin-susceptible *Staphylococcus aureus*; n -- number

Two of the three strains identified as *S. epidermidis* were identified by MALDI-TOF as *Micrococcus luteus*/*lylae*, and one was identified as *Arcanobacterium haemolyticum*. One isolate was identified as *Corynebacterium amycolatum*, which should have been identified as *S. aureus*. One of the two isolates, which should have been identified as *Staphylococcus hominis*, was identified as *Bacillus cereus*/*subtilis*, and the other was identified as *Corynebacterium jeikeium*. As a result, 138 (92%) out of 150 isolates were correctly identified, while the number misidentified was only 12. In fact, all false identifications at the genus or species level were also associated with Gram-positive bacteria (Table [III](#tbl3){ref-type="table"}).

###### 

Distribution of the identified species according to MALDI-TOF MS results when working with both methods.

![](pjm-69-2-165-t003)

  --------------------------------------------------------------------------------------------------
  Organisms                           MALDI-TOF\               Rapid method\      Routine method\
                                      Biotyper scores\         n                  n
                                      \< 1.7; 1.7--2.0; ≥ 2\                      
                                      n n n Total                                 
  ----------------------------------- ------------------------ ------------------ ------------------
  **[Gram-positive bacteria]{.ul}**   **[116]{.ul}**           **[116]{.ul}**     **[116]{.ul}**

  *Staphylococcus aureus*             0 0 8 8                      7                  8

  *Staphylococcus epidermidis*        0 12 36 48                 45                 48

  *Staphylococcus hominis*            0 2 16 18                  16                 18

  *Staphylococcusschleiferi*          0 0 4 4                      4                  4

  *Staphylococcus haemolyticus*       0 0 2 2                      2                  2

  *Staphylococcus capitis*            0 0 2 2                      2                  2

  *Staphylococcus warneri*            0 0 2 2                      2                  2

  *Enterococcus faecalis*             0 0 18 18                  18                 18

  *Enterococcus faecium*              0 0 2 2                      2                  2

  *Arcanobacterium haemolyticum*      0 1 1 2                      3                  2

  *Bacillus cereus*/*subtilis*        0 0 0 0                      1                  0

  *Bacillus subtilis*                 0 0 2 2                      2                  2

  *Dermacoccus nishinomiyaensis*      0 0 2 2                      2                  2

  *Micrococcus luteus*/*lylae*        0 1 1 2                      4                  2

  *Corynebacterium amycolatum*        0 1 1 2                      3                  2

  *Corynebacterium jeikeium*          0 1 1 2                      3                  2

  **[Gram-negative bacteria]{.ul}**   **[30]{.ul}**              **[30]{.ul}**      **[30]{.ul}**

  *Escherichia coli*                  0 0 15 15                  15                 15

  *Pseudomonas aeruginosa*            0 1 4 5                      5                  5

  *Klebsiella pneumoniae*             0 0 5 5                      5                  5

  *Stenotrophomonas maltophilia*      0 0 3 3                      3                  3

  *Acinetobacter baumannii*           0 0 2 2                      2                  2

  **[Yeasts]{.ul}**                   **[4]{.ul}**                 **[4]{.ul}**       **[4]{.ul}**

  *Candida parapsilosis*              0 0 2 2                      2                  2

  *Candida tropicalis*                0 0 2 2                      2              

  Total                               0 19 131 150             150                150
  --------------------------------------------------------------------------------------------------

MALDI-TOF MS -- matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; n -- number

These values were compared with the identification and antibiotic susceptibility results obtained by the routine procedures. According to this comparison, for 138 (92%) of the 150 strains studied, the same results for the identification testing were obtained using both methods, demonstrating complete consistency between the two methods. However, a discrepancy was detected between the two methods for 12 (8%) strains, with small differences observed in only Gram-positive bacteria. Conversely, for the 30 Gram-negative strains, 100% consistency was observed between the rapid method and the MALDI-TOF MS system. Two samples were terminated without processing because they contained more than one type of microorganism (polymicrobial) and were not evaluated. Therefore, when the identification and antibiotic susceptibility tests of all the Gram-negative bacteria were compared, no discrepancy occurred between the results from either method (of the 150 strains, 30 \[20%\] Gram-negative bacilli continued to be studied; the same identification and antibiotic susceptibility results were obtained with both methods). No difference was observed between the results obtained by both methods for all strains of enterococci belonging to Gram-positive bacteria (20 \[13.3%\] of the 150 strains). However, when other Gram-positive bacteria were evaluated, a small inconsistency (identification of different microorganisms at the genus or species level using each method) equal to 8% was observed between these methods. In addition, this inconsistency was also observed in the results obtained for the Gram-positive strains, which can be regarded as indicative of contamination (Table [IV](#tbl4){ref-type="table"}).

###### 

Analysis of the compatibility between the identification results of the rapid method when compared with the MALDI-TOF MS.

![](pjm-69-2-165-t004)

  ----------------------------------------------------------------------------------
  Bacteria                 Full consistency\   Misidentified\      Not identified\
                           n (%)               n (%)               n (%)
  ------------------------ ------------------- ------------------- -----------------
  Gram-positive bacteria   104 (89.7)                  12 (10.3)   0

  Gram-negative bacteria     30 (100)          0                   0

  Yeasts                       4 (100)         0                   0

  Total                    138 (92)               12 (8)           0
  ----------------------------------------------------------------------------------

MALDI-TOF MS -- matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; n -- number

The agreement for the AST results performed by both methods are the same in terms of the MIC values (100% of similarity) for most of the antimicrobials (e.g., vancomycin, teicoplanin, ampicillin, and linezolid), whereas the lowest agreement value was obtained for the piperacillin/tazobactam combination (Table [V](#tbl5){ref-type="table"}). However, when all the antibiotic susceptibility results between the two methods were examined, the ratio of the full agreement was 97.4%, the VME ratio (0.8%) was slightly higher than the ME ratio (0.1%), and the mE value was found as expected: 33 (1.7%) (Table [VI](#tbl6){ref-type="table"}).

###### 

Distribution of the resistance profiles for Gram-positive and Gram-negative bacteria as a result of the antibiotic susceptibility testing when both methods were applied.

![](pjm-69-2-165-t005)

  Antibiotics                   The rapid method, n (%)   The routine method, n (%)                                               
  ----------------------------- ------------------------- --------------------------- ------------ ------------------ ----------- -------------
  Amikacin                          28 (93.3)             --                          2 (6.7)          28 (93.3)      --          2 (6.7)
  Ampicillin                        18 (19.1)             --                          76 (80.9)        18 (19.1)      --          76 (80.9)
  Amoxicillin/Clavulanic acid       18 (15.8)             --                          96 (84.2)        18 (15.8)      --          96 (84.2)
  Aztreonam                      18 (60)                  1 (3.3)                     11 (36.7)     15 (50)           --          15 (50)    
  Cefepime                          20 (66.7)             --                          10 (33.3)        14 (46.7)      --          16 (53.3)  
  Cefoxitin                     --                        36 (41.9)                   50 (58.1)    --                 35 (40.7)   51 (59.3) 
  Ceftazidime                       10 (33.3)             10 (33.3)                   10 (33.3)        10 (33.3)      10 (33.3)   10 (33.3) 
  Ceftriaxone                    18 (60)                  --                          12 (40)       18 (60)           --          12 (40)   
  Ciprofloxacin                     82 (66.1)             --                          42 (33.9)        66 (53.2)      10 (8.1)    48 (38.7)
  Colistin                         30 (100)               --                          --              30 (100)        --          --
  Clindamycin                       50 (53.2)             1 (1.1)                     43 (45.7)          51 (554.3)   --          43 (45.7)
  Daptomycin                        71 (75.5)             23 (24.5)                   --               65 (69.1)      29 (30.9)   --
  Ertapenem                         28 (93.3)             --                          2 (6.7)          28 (93.3)      --          2 (6.7)
  Erythromycin                      14 (14.9)             --                          80 (85.1)        14 (14.9)      --          80 (85.1)
  Fusidic acid                      35 (40.7)             --                          51 (59.3)        36 (41.9)      --          50 (58.1)
  Gentamicin                        66 (53.2)             --                          58 (46.8)        66 (53.2)      1 (0.8)     57 (50)
  Imipenem                          28 (93.3)             --                          2 (6.7)          28 (93.3)      --          2 (6.7)
  Meropenem                         28 (93.3)             --                          2 (6.7)          28 (93.3)      --          2 (6.7)
  Linezolid                         94 (100)              --                          --               94 (100)       --          --
  Oxacillin                         12 (12.8)             --                          82 (87.2)        12 (12.8)      --          82 (87.2)
  Piperacillin/Tazobactam           10 (33.3)             10 (33.3)                   10 (33.3)        16 (53.3)      2 (6.7)     12 (40)   
  Rifampin                        62 (66)                 --                          32 (34)        62 (66)          --          32 (34)   
  Teicoplanin                       94 (100)              --                          --               94 (100)       --          --
  Tetracycline                      35 (40.7)             --                          51 (59.3)        35 (40.7)      --          51 (59.3)
  Tigecycline                       84 (89.4)             8 (8.5)                     2 (2.1)          86 (91.5)      6 (6.4)     2 (2.1)   
  TMP/SX                            55 (44.4)             --                          69 (55.6)        51 (41.1)      3 (2.4)     70 (56.5)
  Vancomycin                       94(100)                --                          --              94 (100)        --          --
  Total                         1102 (55.5)               89 (4.5)                    793 (40)     1077 (54.3)        96 (4.8)    811 (40.9)

n -- number; I -- intermediate; R -- resistant; S -- susceptible; TMP/SX -- Trimethoprim/Sulfamethoxazole

###### 

Categorical distribution of discrepancies in the antibiotic susceptibility results of the rapid method compared to the routine method.

![](pjm-69-2-165-t006)

  -------------------------------------------------------------------------------------------
  Antibiotics                   Agreement\      mEs\         MEs\        VMEs\       Total\
                                n (%)           n (%)        n (%)       n (%)       n
  ----------------------------- --------------- ------------ ----------- ----------- --------
  Amikacin                          30 (100)                                             30

  Ampicillin                        94 (100)                                             94

  Amoxicillin/Clavulanic acid   114 (100)                                              114

  Aztreonam                         26 (86.7)     1 (3.3)                  3 (10)        30

  Cefepime                      24 (80)                                    6 (20)        30

  Cefoxitin                       85 (98.8)       1 (1.2)                                86

  Ceftazidime                     30 (100)                                               30

  Ceftriaxone                     30 (100)                                               30

  Ciprofloxacin                 108 (87.1)      10 (8.1)                   6 (4.8)     124

  Colistin                        30 (100)                                               30

  Clindamycin                       93 (98.9)     1 (1.1)                                94

  Daptomycin                        88 (93.6)     6 (6.4)                                94

  Ertapenem                       30 (100)                                               30

  Erythromycin                    94 (100)                                               94

  Fusidic acid                      85 (98.8)                  1 (1.2)                   86

  Gentamicin                    123 (99.2)        1 (0.8)                              124

  Imipenem                        30 (100)                                               30

  Meropenem                       30 (100)                                               30

  Linezolid                       94 (100)                                               94

  Oxacillin                       94 (100)                                               94

  Piperacillin/Tazobactam           22 (73.3)     8 (26.7)                               30

  Rifampin                        94 (100)                                               94

  Teicoplanin                     94 (100)                                               94

  Tetracycline                    86 (100)                                               86

  Tigecycline                       92 (97.9)     2 (2.1)                                94

  TMP/SX                        120 (96.8)        3 (2.4)                  1 (0.8)     124

  Vancomycin                      94 (100)                                               94

  Total                         1934 (97.4)     33 (1.7)     1 (0.1)     16 (0.8)    1984
  -------------------------------------------------------------------------------------------

n -- number; mEs -- minor errors; MEs -- major errors; TMP/SX -- Trimethoprim/Sulfamethoxazole; VMEs -- very major errors

Discussion {#sec5}
==========

To date, a limited number of studies have been conducted to use rapid methods to determine the type of organisms that grow in blood cultures and evaluate their antibiotic susceptibility. However, the rapid identification of infectious agents circulating in patients' blood and the determination of the species and the correct antibiotic to be used will shorten the treatment time by 12 hours, and reduce the cost. The early identification of bloodstream infections allows for the early modification of antimicrobial treatment and a diminished need for other diagnostic tests. Thus, patients' hospital stay can be shortened, and expenditures on patients can be reduced ([@bib3]).

In a study conducted by a group of researchers, 501 microorganisms from blood-circulating infections were detected in the patients with bacteremia or candidiasis with MALDI-TOF with the Antimicrobial Stewardship Team test. MALDI-TOF analysis of 245 patients in the intervention group and 256 patients in the preintervention group showed reductions in the identification times (84 hours to 56 hours), effective antibiotic treatment times (30 to 20 hours), and optimal antibiotic treatment times (90 to 47 hours) for the organism ([@bib12]). Our study reports the identification and antibiotic susceptibility tests that are much shorter (\< 24 hours) than conventional tests (routinely \> 72 hours). In contrast to routine tests, this study achieved 97% success without having to use any expensive methods.

In a study ([@bib8]), nucleic acid-based tests were performed on Gram-positive and Gram-negative bacteria from blood cultures; the test was designed to rapidly identify multiple bacterial strains and the resistance associated with these strains. This method was compared with the routine method for 117 isolates, and the identification and antibiotic resistance markers were reported as correct and accurate, achieving 97% and 92% rates of detection of pathogens from the blood cultures and reduced laboratory times. In our study, the observed 92% accurate identification and 97% antibiotic susceptibility compliance results were similar.

In another study ([@bib18]), a total of 102 positive blood cultures were tested with the Verigene BC-GN test, which detected certain Gram-negative bacteria and selected resistance genes. Ninety-eight percent of the isolates were correctly identified, and 29% were identified as those carrying the resistance genes (CTX-M, KPC, VIM, and OXA genes). The other researchers ([@bib11]) included 54 blood culture samples that gave positive signals between 7 and 23 hours using the Verigene BC-GN test, and correctly identified 51 of these samples as Gram-negative bacilli, whereas [@bib18]) reported that they correctly identified the full-length carbapenemase enzyme. In a test run, the identification of the organisms was reported to be faster than the conventional method by an average of 24 hours. The other group ([@bib22]) studied the blood cultures of 126 patients with Gram-negative bacteremia using an antimicrobial stewardship program test. In a study evaluating the VITEK 2 system with the Verigene BC-GN test, the mean survival rate in the optimal treatment was shorter in the post-intervention group than in the pre-intervention group (38 to 49 hours, respectively). The rapid method in our study does not require any additional costs, systems, or devices, and it is 24 hours shorter than the method in the abovementioned study. We believe our method can be used for all bacteria instead of only certain bacteria.

The MALDI-TOF and a VITEK 2 system were used together in a study by Machen and coworkers ([@bib16]) performed to the same-day identification and the full panel antimicrobial susceptibility testing of bacteria from a total of 100 positive blood culture bottles. Compared to conventional methods, the direct results were 94% correctly identified with the VITEK system, and the identification and antibiograms were concluded on the same day. In our study, direct results were also reported, with a high success rate of 94% being achieved (without 24 hours of incubation) using 5 ml of liquid from the blood culture fluid and without the need for a device that adds costs to the conventional method.

In a study conducted by another group of researchers ([@bib1]), the detection of bacterial and fungal resistance genes in the strains directly identified in 617 positive blood cultures was performed using a direct rapid multiplex PCR (rmPCR). It was followed by the evaluation of the treatment duration and mortality. The shortest period after Gram staining needed to appropriate evaluation of antimicrobial susceptibility was achieved by rmPCR. These results allowed for the reduction of mortality and the use of antibiotics. Because we were working with fewer samples in our study (which would not significantly change the results), the rapid delivery of blood culture results was critical to the patient; in terms of cost, the centrifugation of blood culture bottles with positive signals required no extra cost, and this method was used to obtain faster results (\< 24 hours).

In a study by [@bib23], a total of 212 patient samples, 179 of which were positive blood cultures and 33 of which were isolated broth species, were prepared and processed for MALDI-TOF analysis. In this study, 42 strains (12 *Propionibacterium acnes* and seven *S. epidermidis*) with spectral scores \< 1.7 could not be identified. Twenty-four strains with scores between 1.7 and 1.9 were correctly identified (six were *S. epidermidis*). The strains with scores of 1.9 were correctly identified at the species level. Similarly, in our study, the species determination and antibiotic susceptibility testing of strains from a single-species culture in the blood cultures were performed using a rapid method. Alternatively, for rapid reporting (97% success) of the antibiotic susceptibility results, we used a direct analysis with a centrifugation process. Notably, the use of mass spectrometry technology can only be established in large laboratories.

The other researchers ([@bib15]) studied 57 blood cultures that were collected from different clinics and found to be a single-species culture of Gram-positive cocci by Gram staining. The addition of saponin in the new procedure was compared with the routine method. Discrepancies between the two methods were resolved by ID32 Staph or by Rapid ID32 Strep and E-test. With the new method, 44 (80%) of the Gram-positive cocci were detected as CoNS (34 \[62%\] *S. epidermidis*). In our study, unlike the one above, not only Gram-positive bacteria but also other bacteria and yeasts were studied. In addition, saponin or a similar substance was not used in this study. Among the identification values obtained by the rapid method, the CoNS rate was slightly lower (62%). Although our antibiotic susceptibility findings were similar, we notably had few VMEs, which maybe because of the presence of gel in the tubes.

In another study ([@bib7]), Gram staining was performed after samples were cultured on blood; this method was performed on 400 positive-signal blood cultures on weekdays between 8:00 am and 3:00 pm. Samples that were a single species culture after the Gram staining were included in the study. While 358 (89.5%) isolates were identified correctly by VITEK MS, 343 (85.8%) were identified correctly at the species level, and 15 (3.7%) were identified correctly at the genus level. Of these definitions, 146 (96.1%) isolates of 152 Gram-negative bacilli (78 *E. coli* and 25 *Klebsiella* species isolates) were correctly identified, while 197 (79.4%) isolates of 248 Gram-positive organisms (76 of 95 CoNS and 56 of 58 *S. aureus*) were correctly identified. In our study, Gram-negative bacilli and yeasts were correctly identified in 100%, and Gram-positive bacteria were correctly identified in approximately 90%. These identifications were obtained without any culturing on media or incubation after centrifugation; instead, the identification occurred by loading directly into the culture antibiogram device. In addition, enterococci were also completely identified when compared with MALDI-TOF MS.

In one study ([@bib24]), 485 positive specimens were evaluated by injecting various body fluids into blood culture bottles. Then, the researchers combined MALDI-TOF MS with a VITEK AST system and conducted rapid microbial identification (RMI), and rapid multiple AST (RMAST). Then, the RMAST results were compared with the standard method results. Discrepancies in the MIC values were resolved by broth dilution, according to CLSI (2015) guidelines. RMI correctly identified Gram-negative and Gram-positive bacteria (98.9%, and 87.2%, respectively), and fungi (75.7%). As a result, the RMI and RMAST were completed 18--36 hours in advance of the report notification. In our study, only blood cultures were evaluated. A longer centrifugation time with a lower speed was utilized. After comparable identification and antibiotic susceptibility testing procedures, similar results were obtained. Our report notifications were made within 24 hours.

Recently, in a study conducted by Campigottoa et al. ([@bib6]), MALDI-TOF MS analysis was used for the identification of bacteria directly from blood cultures, followed by antibiotic susceptibility tests and rapid determination of methicillin-resistance and betalactam-resistance status. A total of 125 positive blood cultures sent from various intensive care units were included in the study. The VITEK 2 system and appropriate AST cards were used to determine the antibiotic susceptibility, and standard procedures were applied. When compared with the routine method, 91.2% were correctly identified at the genus level, 82.4% had species-level compatibility, and eight unidentified isolates at the genus level were Gram-positive organisms. Gram-negative bacteria were detected at a high species level of 100% and 93%, respectively. All four fungal isolates *C. albicans, C. parapsilosis*, and *C. tropicalis* were correctly identified at the species level. In contrast to the above study, in our study, the centrifugation time was longer, the rpm was lower, and the bacterial suspension was prepared and loaded directly onto the Phoenix 100 instrument. Similar error rates (2.6% in total) and agreement (97%) were observed. Furthermore, in our study, the goal of reporting results in 24 hours was successfully achieved.

Conclusions {#sec6}
===========

The search for methods that do not require additional financing and are widely available is on-going. In this study, 5 ml of blood samples were taken directly from blood cultures with positive signals, and the results were obtained within 24 hours. It was achieved with centrifugation, Gram staining, and an appropriate antimicrobial panel (Gram-positive or Gram-negative). The Gram-negative strains were reported with 100% consistency, and the Gram-positive strains were reported with 90% consistency among the new and routine methods. For the Gram-positive bacteria that were inconsistently identified with these methods, we believe that further studies in this area will help to distinguish pathogenic and nonpathogenic strains. In particular, we believe that unnecessary antibiotic treatments can be avoided for patients infected with Gram-positive bacteria, which can be identified as contaminants sooner than Gram-negative bacteria. Due to the rapid culture antimicrobial susceptibility testing used in this study, antibiotic therapies could begin early, since the patients' blood culture results will be reported very quickly (in about 12 hours) without the need for extra costs. In addition, since this can shorten the length of hospital stay of patients, medical and economic benefits will be achieved at the national level. We also believe that the volume of the sample taken directly from the bottles should be increased (to at least 10 ml) and that employees should have sufficient experience; then, the efficiency of this method can be higher. However, the most crucial limitation of this method is the presence of more than one species in the blood cultures (polymicrobial cultures). Finally, the rapid method used in the study allows obtaining the diagnosis of bloodstream infections in a short span of 12 hours and with an accuracy of 97% (100% for Gram-negative bacteria).

Thanks to the staff of our hospital's culture laboratory for their contributions.
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AST--

:   antibiotic susceptibility test

BC-GN--

:   Gram-negative blood culture

CLSI--

:   Clinical and Laboratory Standards Institute

CoNS--

:   coagulase-negative *Staphylococcus*

EMB--

:   eosin methylene blue

FA--

:   formic acid

GN--

:   Gram-negative

GP--

:   Gram-positive

HCCA--

:   α-cyano-4-hydroxycinnamic acid matrix solution

ID--

:   identification

MALDI-TOF MS--

:   matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

ME--

:   major error

mE--

:   minor error

MIC--

:   minimum inhibitory concentration

MRSA:

:   methicillin-resistant *Staphylococcus aureus*

RMAST--

:   rapid multiple AST

RMI--

:   rapid microbial identification

rmPCR--

:   rapid multiplex PCR

SBA--

:   sheep blood agar

VME--

:   very major error
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